AORT Earnings Date: Nov 5, 2026 (Estimated) — Artivion, Inc.
NYSE · Healthcare · Medical Devices
Updated
When is AORT's next earnings date?
Artivion, Inc. (AORT) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.06 on revenue of $121.0M.
How did AORT do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Artivion, Inc. posted EPS of $0.13 versus the $0.00 estimate, a beat of 30.0%. Revenue was $125.8M against a $120.0M estimate. The stock's 1-day post-earnings move was +2.1%.
How much does AORT stock move after earnings?
AORT beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.6% (up or down) in the day after earnings.
About Artivion, Inc.
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | 0.00 | 0.13 | +30.00% | $125.8M | ✅ Beat | +2.07% | +6.93% | -3.76% |
| 2026-05-07 | Q1 2026 | 0.11 | 0.08 | -27.27% | $116.3M | ❌ Miss | -28.26% | -35.26% | -42.43% |
| 2026-02-12 | Q4 2025 | 0.16 | 0.17 | +6.25% | $116.0M | ✅ Beat | -9.96% | -5.71% | -8.00% |
| 2025-11-06 | Q3 2025 | 0.15 | 0.16 | +6.67% | $113.4M | ✅ Beat | -5.54% | -4.02% | -7.22% |
| 2025-02-24 | Q4 2024 | 0.04 | 0.00 | -100.00% | $97.3M | ❌ Miss | -8.22% | -9.77% | -11.42% |
| 2024-11-07 | Q3 2024 | -0.06 | 0.12 | +300.00% | $95.8M | ✅ Beat | -0.93% | -6.87% | +0.07% |
| 2024-08-08 | Q2 2024 | -0.06 | 0.07 | +216.67% | $98.0M | ✅ Beat | -1.90% | -0.36% | -3.87% |
| 2024-02-15 | Q4 2023 | -0.10 | 0.11 | +210.00% | $93.7M | ✅ Beat | +4.27% | +12.36% | +10.37% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $125.8M total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| Aortic Stent Grafts | 36.9% | $46.4M | +16.5% | $28.6M | $30.1M | $36.6M | $39.8M |
| On X | 24.3% | $30.5M | +19.3% | $21.5M | $22.2M | $21.6M | $25.6M |
| Preservation Services | 20.6% | $25.9M | +1.3% | $24.5M | $22.6M | $20.2M | $25.5M |
| Surgical Sealants | 15.3% | $19.3M | 0.0% | $18.4M | $19.9M | $18.1M | $19.3M |
| Other Products | 2.9% | $3.7M | +34.8% | $2.7M | $2.4M | $2.5M | $2.7M |
By region
Q2 FY26 · $125.8M total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| North America | 49.6% | $62.3M | +8.3% | $49.1M | $49.3M | $47.8M | $57.6M |
| Europe, the Middle East, and Africa Segments | 35.4% | $44.5M | +15.1% | $30.4M | $33.4M | $37.0M | $38.7M |
| Asia Pacific | 9.7% | $12.2M | +9.3% | $10.4M | $9.6M | $8.2M | $11.1M |
| Latin America | 5.3% | $6.7M | +20.7% | $5.9M | $5.1M | $5.9M | $5.6M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.